MaaT013: Positive Topline Phase 3 results

See more

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

May 15, 2025

May 15, 2025: MaaT Pharma : Présentation investisseurs, Stratégie et Perspectives 2025 – La Bourse et La Vie (French Only)

May 14, 2025

May 14, 2025: MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress

May 14, 2025

May 14, 2025: MaaT Pharma to Hold Annual General Meeting on June 20, 2025

Like what you see? See more posts

Our upcoming events

Event
May 15, 2025

EHA 2025 Congress

• June 12-15, 2025 – EHA 2025 Congress, Milan, Italy
MaaT Pharma
Event
May 15, 2025

BIO International Convention 2025

• June 16-19, 2025 – BIO International Convention 2025, Boston, MA
MaaT Pharma
Event
May 15, 2025

Portzamparc Conference Mid & Small Caps 2025

• June 18-19, 2025 – Portzamparc Conference Mid & Small Caps 2025, Paris, France
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers